Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up
- PMID: 25986946
- DOI: 10.1136/gutjnl-2015-309598
Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up
Abstract
Background: Endoscopic mucosal healing is an established treatment target for UC, yet the value of achieving histological remission remains unclear.
Aims: To evaluate histological remission compared to endoscopic mucosal healing for predicting patient outcomes in UC.
Methods: Blinded assessment of endoscopic and histological measures of disease activity was performed on patients with established UC at baseline. Concordance and prognostic values of endoscopic mucosal healing (defined by Baron score ≤1) and histological remission (defined by Truelove and Richards' index) for predicting outcomes of corticosteroid use, hospitalisation and colectomy were determined over a median 6 years follow-up, including κ statistics and Cox regression multivariate analysis.
Results: 91 patients with UC were followed up for a median 72 months (IQR 54-75 months). Overall, concordance between endoscopic and histological remission was moderate (κ=0.56, 95% CI 0.36 to 0.77); 24% patients had persistent inflammation despite endoscopic remission. Histological remission predicted corticosteroid use and acute severe colitis requiring hospitalisation over the follow-up period (HR 0.42 (0.2 to 0.9), p=0.02; HR 0.21 (0.1 to 0.7), p=0.02; respectively), whereas endoscopic mucosal healing did not (HR 0.86, 95% CI 0.5 to 1.7, p0.65; HR 0.83 95% CI 0.3 to 2.4, p0.74; respectively).
Conclusions: Histological remission is a target distinct from endoscopic mucosal healing in UC and better predicts lower rates of corticosteroid use and acute severe colitis requiring hospitalisation, over a median of 6 years of follow-up. Our findings support the inclusion of histological indices in both UC clinical trials and practice, towards a target of 'complete remission'.
Keywords: HISTOPATHOLOGY; INFLAMMATORY BOWEL DISEASE; MUCOSAL REPAIR; ULCERATIVE COLITIS.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Similar articles
-
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.Gastroenterology. 2011 Oct;141(4):1194-201. doi: 10.1053/j.gastro.2011.06.054. Epub 2011 Jun 30. Gastroenterology. 2011. PMID: 21723220 Clinical Trial.
-
Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes.Clin Gastroenterol Hepatol. 2017 Oct;15(10):1557-1564.e1. doi: 10.1016/j.cgh.2017.02.016. Epub 2017 Feb 24. Clin Gastroenterol Hepatol. 2017. PMID: 28238954 Free PMC article.
-
Histological healing after infliximab induction therapy in children with ulcerative colitis.World J Gastroenterol. 2015 Oct 7;21(37):10654-61. doi: 10.3748/wjg.v21.i37.10654. World J Gastroenterol. 2015. PMID: 26457025 Free PMC article.
-
Clinical relevance of endoscopic assessment of inflammation in ulcerative colitis: Can endoscopic evaluation predict outcomes?World J Gastroenterol. 2016 Nov 14;22(42):9324-9332. doi: 10.3748/wjg.v22.i42.9324. World J Gastroenterol. 2016. PMID: 27895420 Free PMC article. Review.
-
Is histological healing a feasible endpoint in ulcerative colitis?Expert Rev Gastroenterol Hepatol. 2021 Jun;15(6):665-674. doi: 10.1080/17474124.2021.1880892. Epub 2021 Jan 29. Expert Rev Gastroenterol Hepatol. 2021. PMID: 33481635 Review.
Cited by
-
Protective effect of a newly probiotic Lactobacillus reuteri LY2-2 on DSS-induced colitis.Eur J Nutr. 2024 Nov 15;64(1):5. doi: 10.1007/s00394-024-03535-3. Eur J Nutr. 2024. PMID: 39546032
-
Comparative Value of CRP and FCP for Endoscopic and Histologic Remissions in Ulcerative Colitis.Diagnostics (Basel). 2024 Oct 14;14(20):2283. doi: 10.3390/diagnostics14202283. Diagnostics (Basel). 2024. PMID: 39451607 Free PMC article.
-
Artificial intelligence and machine learning technologies in ulcerative colitis.Therap Adv Gastroenterol. 2024 Sep 5;17:17562848241272001. doi: 10.1177/17562848241272001. eCollection 2024. Therap Adv Gastroenterol. 2024. PMID: 39247718 Free PMC article. Review.
-
Histologic improvement predicts endoscopic remission in patients with ulcerative colitis.Sci Rep. 2024 Aug 27;14(1):19926. doi: 10.1038/s41598-024-68372-0. Sci Rep. 2024. PMID: 39198522 Free PMC article.
-
Absence of Paneth Cell Metaplasia to Predict Clinical Relapse in Ulcerative Colitis with Endoscopically Quiescent Mucosa.Dig Dis Sci. 2024 Oct;69(10):3932-3941. doi: 10.1007/s10620-024-08581-9. Epub 2024 Aug 7. Dig Dis Sci. 2024. PMID: 39110367
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical